Credit Suisse Group Reiterates “$57.00” Price Target for Alkermes (ALKS)
Alkermes (NASDAQ:ALKS) has been assigned a $57.00 price objective by Credit Suisse Group in a report released on Friday. The firm presently has a “buy” rating on the stock. Credit Suisse Group’s price objective indicates a potential upside of 27.40% from the company’s previous close.
ALKS has been the subject of a number of other research reports. Zacks Investment Research upgraded Alkermes from a “hold” rating to a “buy” rating and set a $61.00 target price for the company in a report on Monday, January 8th. Cowen decreased their target price on Alkermes to $55.00 and set an “outperform” rating for the company in a report on Monday, April 2nd. BidaskClub downgraded Alkermes from a “hold” rating to a “sell” rating in a report on Saturday, January 20th. Cantor Fitzgerald restated a “hold” rating and set a $50.00 target price on shares of Alkermes in a report on Tuesday, February 20th. Finally, ValuEngine cut Alkermes from a “hold” rating to a “sell” rating in a research note on Monday, April 2nd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $59.42.
Shares of Alkermes stock opened at $44.74 on Friday. The company has a quick ratio of 2.46, a current ratio of 2.78 and a debt-to-equity ratio of 0.23. The company has a market cap of $7,137.81, a P/E ratio of -120.92 and a beta of 1.82. Alkermes has a 52 week low of $41.15 and a 52 week high of $71.22.
In related news, SVP Mark Stejbach sold 10,880 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $70.50, for a total value of $767,040.00. Following the sale, the senior vice president now directly owns 54,893 shares of the company’s stock, valued at $3,869,956.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Paul J. Mitchell sold 1,000 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $56.77, for a total value of $56,770.00. Following the completion of the sale, the director now directly owns 9,000 shares in the company, valued at $510,930. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 89,973 shares of company stock worth $5,533,216. 5.34% of the stock is owned by insiders.
A number of hedge funds have recently modified their holdings of the stock. CIBC Asset Management Inc grew its stake in shares of Alkermes by 12.6% in the fourth quarter. CIBC Asset Management Inc now owns 7,287 shares of the company’s stock worth $399,000 after acquiring an additional 818 shares during the last quarter. Public Employees Retirement Association of Colorado grew its stake in shares of Alkermes by 3.2% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 31,504 shares of the company’s stock worth $1,724,000 after acquiring an additional 970 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Alkermes by 4.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,855 shares of the company’s stock worth $1,908,000 after acquiring an additional 1,462 shares during the last quarter. Amalgamated Bank grew its stake in shares of Alkermes by 5.7% in the fourth quarter. Amalgamated Bank now owns 30,459 shares of the company’s stock worth $1,667,000 after acquiring an additional 1,634 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Alkermes by 1.0% in the third quarter. Dimensional Fund Advisors LP now owns 198,135 shares of the company’s stock worth $10,076,000 after acquiring an additional 2,027 shares during the last quarter.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.